Cognetivity Neurosciences To Deploy Wellness App With Dutch Telehealth Firm

Cognetivity Neurosciences (CSE: CGN) has reached the commercialization stage for one of its products. The company this morning announced that via an agreement with Dutch telehealth firm Luscii Healthtech BV, the company will be deploying its wellness app, OptiMind.

The arrangement will see the deployment of Cognetivity’s OptiMind app for its sophisticated cognitive measurement capabilities. The tech will be used by Luscii to better understand the impact of the firms HR policies and corporate wellness initiatives. Luscii is currently the market leader when it comes to telehealth within the Netherlands, with the firms products deployed in over half the hospitals located within the country.

Optimind has been developed based on the firms flagship clinical product, ICA, which provides medical grade cognitive assessment functionality. The app is focused on the personalized tracking and management of cognitive performance, with a focus on providing feedback loops between employees and employers for the monitoring of both wellbeing and risk.

“Many progressive employers have strived to increase the impact of mental wellbeing efforts in the workplace to better support their employees and improve efficiency. Crucially, OptiMind makes it practical and cost-effective to measure the impact of these initiatives. With OptiMind based on the same underlying science and technology that underpins our clinical products, and therefore benefiting from not only clinical validation but also speed and ease of use, our fundamentally different approach to cognitive testing is now opening an entirely new way for companies to support their staff.”

Dr Sina Habibi, CEO of Cognetivity Neuroscience

Cognetivity Neurosciences last traded at $0.84 on the CSE.

FULL DISCLOSURE: Cognetivity Neurosciences Ltd is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Cognetivity Neurosciences Ltd on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply